News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ReVision Optics, Inc. Advances PresbyLens into Phase 3 Clinical Trial for Improving Near Vision in Patients with Presbyopia



6/11/2012 10:14:40 AM

LAKE FOREST, Calif.--(BUSINESS WIRE)--ReVision Optics®, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, announces the advancement of its proprietary product PresbyLens™ into the final phase of its U.S. clinical trial under an Investigational Device Exemption (IDE). PresbyLens is a clear, circular corneal inlay comprised of approximately 80% water and is less than half the thickness of a human hair.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES